<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857961</url>
  </required_header>
  <id_info>
    <org_study_id>14271</org_study_id>
    <secondary_id>MTE07</secondary_id>
    <secondary_id>I5E-MC-TSAG</secondary_id>
    <nct_id>NCT00857961</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations</brief_title>
  <official_title>A Phase II, Randomised, Four-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered Dose (MD) LotionÂ® Formulations and Doses in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testosterone replacement treatment is the most effective way of treating hypogonadism in men.
      Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study
      will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also
      assess safety of the product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Time of Maximal Concentration (Tmax)</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Tmax is the time at which the maximum concentration (Cmax) was attained during the 24 hour period on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Total Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Cmax is the maximum observed serum concentration of total testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Dihydrotestosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Cmax is the maximum observed serum concentration of dihydrotestosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Free Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Cmax is the maximum observed serum concentration of free testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Degree of Fluctuation (DF)</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Degree of fluctuation in serum concentration calculated as ((Cmax-Cmin)/Cavg) x 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Area Under the Time Concentration Curve [AUC(0-24h)]</measure>
    <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
    <description>Area under the serum concentration versus time curve was calculated using the linear trapezoidal rule from time 0 to 24 hours on Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline through 7 days of each cycle of four treatments and follow-up (up to 38 days)</time_frame>
    <description>A listing of adverse events is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>3 mL (30 mg) of 1% Testosterone MD-Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mL (60 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone MD-Lotion</intervention_name>
    <description>Administered Topically</description>
    <arm_group_label>3 mL (30 mg) of 1% Testosterone MD-Lotion</arm_group_label>
    <arm_group_label>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <arm_group_label>3 mL (60 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <arm_group_label>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</arm_group_label>
    <other_name>LY900011</other_name>
    <other_name>Axiron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male study participants with a prior documented diagnosis of hypoandrogenism as
             evidenced by previously documented: Hypothalamic, pituitary or testicular disorder or
             a Serum testosterone less than or equal to 300 ng/dL

          -  Were receiving, or in the investigator's opinion were eligible to receive treatment
             for hypoandrogenism

          -  Body Mass Index (BMI) less than 35 kg/m^2

          -  Passed the required laboratory and physical screening tests

          -  Haemoglobin levels at screening greater than or equal to 13.0 g/dL

          -  Adequate venous access on left or right arm

          -  Able to communicate with study staff, understand the study information sheet and sign
             the written Informed Consent forms; willing to follow and comply with study procedures

        Exclusion Criteria:

          -  Any significant history of allergy and/or sensitivity to the drug products or their
             excipients, including any history of sensitivity to testosterone and/or sunscreens

          -  Any clinically significant chronic illness or finding on screening physical exam
             and/or laboratory testing

          -  Chronic skin disorder (e.g. eczema, psoriasis) likely to interfere with transdermal
             drug absorption

          -  Men with suspected reversible hypoandrogenism (i.e. due to medications, stress)

          -  Any man in whom testosterone therapy is contraindicated, which included those with:

               -  Known or suspected carcinoma (or history of carcinoma) of the prostate or
                  symptoms of benign prostatic hyperplasia and/or symptoms of lower urinary
                  obstruction,

               -  Known or suspected carcinoma (or history of carcinoma) of the breast,

               -  Severe liver damage i.e. cirrhosis, hepatitis or liver tumours,

               -  Active deep vein thrombosis, thromboembolic disorders or a documented history of
                  these conditions,

               -  Significant cerebrovascular or coronary artery disease,

               -  Known or suspected sleep apnoea,

               -  Hematocrit &gt; 51%

          -  Men with clinically significant prostate exam or clinically significant elevated serum
             prostate specific antigen (PSA) level, or age adjusted reference range of PSA values.

          -  Current history of drug or alcohol abuse (more than 4 standard drinks per day and/or
             abnormal liver function tests 3 times the upper limit of the normal range values)

          -  Men taking concomitant medications that affect sex hormone binding globulin (SHBG) or
             testosterone concentrations or metabolism, or that were cytochrome P450 inducers or
             inhibitors, anti-coagulants (warfarin), or diabetic medications (insulin),
             anti-histamines

          -  Men involved in sport in which there was screening for anabolic steroids

          -  Men with uncontrolled diabetes (hemoglobin A1c [HbA1c] greater than or equal to 10%)

          -  Men taking any Investigational Product, or who had received an Investigational Product
             within 28 days prior to screening or 5 half-lives (whichever was the longer)

          -  Any contraindication to blood sampling

          -  Study participants who planned to have a surgical procedure during the course of the
             study

          -  Study participants with a partner of child bearing potential who was not willing to
             use adequate contraception (i.e. condoms) for the duration of the study

          -  Study participants whose partners were pregnant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-31- Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>December 15, 2010</results_first_submitted>
  <results_first_submitted_qc>January 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2011</results_first_posted>
  <disposition_first_submitted>September 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 15, 2010</disposition_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days.
All study participants received each of the 4 study treatments:
3 mL (30 mg) of 1% Testosterone metered dose (MD)-Lotion applied to both axilla (1.5 mL to each axilla).
1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied to one axilla.
3 mL (60 mg) of 2% Testosterone MD-Lotion applied to both axilla (1.5 mL to each axilla).
4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied by 3 doses to the axilla (2 X 1.5 mL to one axilla and 1 X 1.5 mL to the other axilla).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days.
All study participants received each of the 4 study treatments:
3 mL (30 mg) of 1% Testosterone metered dose (MD)-Lotion applied to both axilla (1.5 mL to each axilla).
1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied to one axilla.
3 mL (60 mg) of 2% Testosterone MD-Lotion applied to both axilla (1.5 mL to each axilla).
4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied by 3 doses to the axilla (2 X 1.5 mL to one axilla and 1 X 1.5 mL to the other axilla).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms/square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Baseline Testosterone</title>
          <units>nanograms per deciliter (ng/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193.2" spread="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Time of Maximal Concentration (Tmax)</title>
        <description>Tmax is the time at which the maximum concentration (Cmax) was attained during the 24 hour period on Day 7.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone MD-lotion.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Time of Maximal Concentration (Tmax)</title>
          <description>Tmax is the time at which the maximum concentration (Cmax) was attained during the 24 hour period on Day 7.</description>
          <population>All participants received all four doses of testosterone MD-lotion.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="1.93" upper_limit="24.00"/>
                    <measurement group_id="O2" value="12.00" lower_limit="1.95" upper_limit="23.93"/>
                    <measurement group_id="O3" value="4.25" lower_limit="0.00" upper_limit="20.00"/>
                    <measurement group_id="O4" value="15.98" lower_limit="1.92" upper_limit="23.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="1.93" upper_limit="24.00"/>
                    <measurement group_id="O2" value="11.93" lower_limit="0.00" upper_limit="23.93"/>
                    <measurement group_id="O3" value="4.25" lower_limit="0.00" upper_limit="24.00"/>
                    <measurement group_id="O4" value="15.98" lower_limit="0.00" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="1.93" upper_limit="24.00"/>
                    <measurement group_id="O2" value="12.00" lower_limit="1.95" upper_limit="23.93"/>
                    <measurement group_id="O3" value="4.25" lower_limit="0.00" upper_limit="20.00"/>
                    <measurement group_id="O4" value="15.98" lower_limit="1.92" upper_limit="23.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Total Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
        <description>Cmax is the maximum observed serum concentration of total testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
          <description>Cmax is the maximum observed serum concentration of total testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
          <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546" spread="266"/>
                    <measurement group_id="O2" value="430" spread="259"/>
                    <measurement group_id="O3" value="590" spread="289"/>
                    <measurement group_id="O4" value="626" spread="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="63"/>
                    <measurement group_id="O2" value="171" spread="59"/>
                    <measurement group_id="O3" value="221" spread="101"/>
                    <measurement group_id="O4" value="238" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg (n=21, n=20, n=21, n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" spread="100"/>
                    <measurement group_id="O2" value="294" spread="150"/>
                    <measurement group_id="O3" value="389" spread="152"/>
                    <measurement group_id="O4" value="432" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Dihydrotestosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
        <description>Cmax is the maximum observed serum concentration of dihydrotestosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Dihydrotestosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
          <description>Cmax is the maximum observed serum concentration of dihydrotestosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
          <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" spread="64.1"/>
                    <measurement group_id="O2" value="69.4" spread="58.6"/>
                    <measurement group_id="O3" value="96.4" spread="46.2"/>
                    <measurement group_id="O4" value="98.6" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="14.4"/>
                    <measurement group_id="O2" value="34.6" spread="26.5"/>
                    <measurement group_id="O3" value="47.8" spread="29.4"/>
                    <measurement group_id="O4" value="49.4" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg (n=21, n=20, n=21, n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="34.0"/>
                    <measurement group_id="O2" value="53.0" spread="45.4"/>
                    <measurement group_id="O3" value="71.4" spread="35.1"/>
                    <measurement group_id="O4" value="76.5" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Free Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
        <description>Cmax is the maximum observed serum concentration of free testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone MD-lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Free Testosterone: Maximal Concentration (Cmax), Minimum Concentration (Cmin), and Average Concentration (Cavg)</title>
          <description>Cmax is the maximum observed serum concentration of free testosterone during the 24 hour period on Day 7. Cmin is the minimum observed serum concentration during the 24 hour period on Day 7. Cavg(0-24) is the average serum concentration calculated during the 24 hour period on Day 7. Calculated as the AUC(0-24) divided by 24 hours.</description>
          <population>All participants received all four doses of testosterone MD-lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="7.5"/>
                    <measurement group_id="O2" value="11.3" spread="5.9"/>
                    <measurement group_id="O3" value="15.9" spread="7.8"/>
                    <measurement group_id="O4" value="16.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.7"/>
                    <measurement group_id="O2" value="4.5" spread="1.3"/>
                    <measurement group_id="O3" value="5.9" spread="2.7"/>
                    <measurement group_id="O4" value="6.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg n=21, n=20, n=21, n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.6"/>
                    <measurement group_id="O2" value="7.6" spread="3.1"/>
                    <measurement group_id="O3" value="10.4" spread="3.9"/>
                    <measurement group_id="O4" value="11.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Degree of Fluctuation (DF)</title>
        <description>Degree of fluctuation in serum concentration calculated as ((Cmax-Cmin)/Cavg) x 100%.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Degree of Fluctuation (DF)</title>
          <description>Degree of fluctuation in serum concentration calculated as ((Cmax-Cmin)/Cavg) x 100%.</description>
          <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
          <units>percent fluctuation in concentration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="55"/>
                    <measurement group_id="O2" value="84" spread="34"/>
                    <measurement group_id="O3" value="91" spread="41"/>
                    <measurement group_id="O4" value="92" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="47"/>
                    <measurement group_id="O2" value="68" spread="25"/>
                    <measurement group_id="O3" value="70" spread="29"/>
                    <measurement group_id="O4" value="65" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="55"/>
                    <measurement group_id="O2" value="84" spread="34"/>
                    <measurement group_id="O3" value="91" spread="41"/>
                    <measurement group_id="O4" value="92" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Area Under the Time Concentration Curve [AUC(0-24h)]</title>
        <description>Area under the serum concentration versus time curve was calculated using the linear trapezoidal rule from time 0 to 24 hours on Day 7.</description>
        <time_frame>Day 7 (0, 2, 4, 8, 12, 16, 20, 24 hours) of each of the four 7 day cycles of treatment</time_frame>
        <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Area Under the Time Concentration Curve [AUC(0-24h)]</title>
          <description>Area under the serum concentration versus time curve was calculated using the linear trapezoidal rule from time 0 to 24 hours on Day 7.</description>
          <population>All participants received all four doses of testosterone-MD lotion. One study participant in the 30 mg of 2% testosterone MD-lotion was not included in any analyses dependent on testosterone/DHT concentration at 24 hours, such as AUC(0-24), Cavg, and comparison of the pre-dose with 24 hours post-dose, since a 24 hour blood sample was not collected.</population>
          <units>h*ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8111" spread="2394"/>
                    <measurement group_id="O2" value="7053" spread="3594"/>
                    <measurement group_id="O3" value="9332" spread="3639"/>
                    <measurement group_id="O4" value="10361" spread="4436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496" spread="816"/>
                    <measurement group_id="O2" value="1271" spread="1090"/>
                    <measurement group_id="O3" value="1712" spread="842"/>
                    <measurement group_id="O4" value="1836" spread="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" spread="61"/>
                    <measurement group_id="O2" value="183" spread="74"/>
                    <measurement group_id="O3" value="250" spread="94"/>
                    <measurement group_id="O4" value="275" spread="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A listing of adverse events is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 7 days of each cycle of four treatments and follow-up (up to 38 days)</time_frame>
        <population>All participants received all four doses of testosterone-MD lotion.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O2">
            <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to one axilla.</description>
          </group>
          <group group_id="O3">
            <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
          </group>
          <group group_id="O4">
            <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
            <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A listing of adverse events is located in the Reported Adverse Events module.</description>
          <population>All participants received all four doses of testosterone-MD lotion.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3 mL (30 mg) of 1% Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
        </group>
        <group group_id="E2">
          <title>1.5 mL (30 mg) of 2% Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days to one axilla.</description>
        </group>
        <group group_id="E3">
          <title>3 mL (60 mg) of 2% Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days to both axilla (1.5 mL to each axilla).</description>
        </group>
        <group group_id="E4">
          <title>4.5 mL (90 mg) of 2% Testosterone MD-Lotion</title>
          <description>Applied once daily for 7 days by three doses to axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

